PURPOSE: Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity. Since lymphocytes express somatostatin receptors, the aim of this study was to evaluate lymphocytic toxicity after PRRT. METHODS: From May 2005 to May 2007, 16 patients affected by neuroendocrine tumors received PRRT with (90)Y-DOTATOC (9), (177)Lu-DOTATATE (5), or both (2). Absolute count, percentage of leukocytes and lymphocytes, and lymphoid subsets (B, T, and NK) were tested at baseline and until 90 days after treatment. RESULTS: A significant lymphoid toxicity (G2-3), mainly affecting B-cells, was observed. It was particularly evident after (90)Y-DOTATOC. Toxicity resulted in being transient and resolved completely at the end of the follow-up (90 days). CONCLUSION: Lymphocyte toxicity in PRRT is mainly due to the selective targeting on B-cells. The relative sparing of T-lymphocytes could explain the absence of clinical side-effects in these patients, such as increased risk of infections. These findings open interesting perspectives in the treatment of B-cell lymphoproliferative disorders.
PURPOSE: Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity. Since lymphocytes express somatostatin receptors, the aim of this study was to evaluate lymphocytic toxicity after PRRT. METHODS: From May 2005 to May 2007, 16 patients affected by neuroendocrine tumors received PRRT with (90)Y-DOTATOC (9), (177)Lu-DOTATATE (5), or both (2). Absolute count, percentage of leukocytes and lymphocytes, and lymphoid subsets (B, T, and NK) were tested at baseline and until 90 days after treatment. RESULTS: A significant lymphoid toxicity (G2-3), mainly affecting B-cells, was observed. It was particularly evident after (90)Y-DOTATOC. Toxicity resulted in being transient and resolved completely at the end of the follow-up (90 days). CONCLUSION: Lymphocyte toxicity in PRRT is mainly due to the selective targeting on B-cells. The relative sparing of T-lymphocytes could explain the absence of clinical side-effects in these patients, such as increased risk of infections. These findings open interesting perspectives in the treatment of B-cell lymphoproliferative disorders.
Authors: Lisa Bodei; Marta Cremonesi; Chiara M Grana; Marco Chinol; Silvia M Baio; Stefano Severi; Giovanni Paganelli Journal: Eur J Nucl Med Mol Imaging Date: 2012-02 Impact factor: 9.236
Authors: Piotr Radojewski; Rebecca Dumont; Nicolas Marincek; Philippe Brunner; Helmut R Mäcke; Jan Müller-Brand; Matthias Briel; Martin A Walter Journal: Eur J Nucl Med Mol Imaging Date: 2015-03-20 Impact factor: 9.236
Authors: Ada H V Repetto-Llamazares; Roy H Larsen; Anna Maria Giusti; Elena Riccardi; Øyvind S Bruland; Pål Kristian Selbo; Jostein Dahle Journal: PLoS One Date: 2014-07-28 Impact factor: 3.240
Authors: Lisa Bodei; Emily Bergsland; Wouter W de Herder; Diego Ferone; Rodney J Hicks; Thomas A Hope; Jolanta Kunikowska; Marianne Pavel; Diane Reidy-Lagunes; Jens Siveke; Jonathan Strosberg; Ulf Dittmer; Ken Herrmann Journal: J Nucl Med Date: 2020-06-23 Impact factor: 10.057
Authors: Chul Kim; Stephen V Liu; Deepa S Subramaniam; Tisdrey Torres; Massimo Loda; Giuseppe Esposito; Giuseppe Giaccone Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751
Authors: Arne Kolstad; Tim Illidge; Nils Bolstad; Signe Spetalen; Ulf Madsbu; Caroline Stokke; Johan Blakkisrud; Ayca Løndalen; Noelle O'Rourke; Matthew Beasley; Wojciech Jurczak; Unn-Merete Fagerli; Michal Kaščák; Mike Bayne; Aleš Obr; Jostein Dahle; Lisa Rojkjaer; Veronique Pascal; Harald Holte Journal: Blood Adv Date: 2020-09-08